The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.

The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The prognosis of intrahepatic cholangiocarcinoma is poor, and a better understanding of intrahepatic cholangiocarcinoma tumor biology is needed to more accurately predict clinical outcome and to suggest potential targets for more effective therapies. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and BRAF are frequently mutated oncogenes that promote carcinogenesis in a variety of tumor types. In this study, we analyze a large set of intrahepatic cholangiocarcinoma tumors (n = 54) for mutations in these genes and compare the clinical outcomes of wild type versus KRAS and BRAF mutant cases. Of 54 cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF, and these were mutually exclusive. These mutant cases were associated with a higher tumor stage at time of resection and a greater likelihood of lymph node involvement. These cases were also associated with a worse long-term overall survival. Therefore, testing for KRAS and BRAF mutations could be a valuable adjunct in improving both prognosis and outcome stratification among patients with intrahepatic cholangiocarcinoma.

[1]  G. Gores,et al.  Erratum: Cholangiocarcinoma (Gastroenterology (2005) 128 (1655-1667)) , 2005 .

[2]  J. Chung,et al.  Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[3]  A. Tannapfel,et al.  mutations in intrahepatic cholangiocarcinoma of the liver , 2000 .

[4]  S. Hussain,et al.  Combined Hepatocellular Cholangiocarcinoma: A Case Report and Review of Literature , 2013, Digestive Diseases and Sciences.

[5]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[6]  Jesse S. Voss,et al.  Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. , 2013, Human pathology.

[7]  S. Kubo,et al.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma , 2004, Cancer Science.

[8]  M. Choti,et al.  Intrahepatic cholangiocarcinoma. , 2019, The Surgical clinics of North America.

[9]  T. Patel,et al.  Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.

[10]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[11]  S. Sheen-Chen,et al.  Surgical treatment of cholangiocarcinoma. , 1997, Hepato-gastroenterology.

[12]  Rameen Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[13]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[14]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[15]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[16]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[17]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[19]  F. Sommerer,et al.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.

[20]  H. Pitt,et al.  p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. , 2000, Journal of hepato-biliary-pancreatic surgery.

[21]  Harada,et al.  Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma , 1999, Histopathology.

[22]  Kathleen M Murphy,et al.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. , 2010, The Journal of molecular diagnostics : JMD.

[23]  P. Argani,et al.  The V599E BRAF mutation is uncommon in biliary tract cancers , 2004, Modern Pathology.